KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions w
Polybromo-1 ( PBRM1 ) loss-of-function mutations are present in a fraction of biliary tract cancers (BTCs). PBRM1 , a subunit of the PBAF chromatin-remodeling complex, is invol
